Jeffrey L. Cummings (ed.)

Progress in Neurotherapeutics and Neuropsychopharmacology

Herausgeber: Cummings, Jeffrey L.

• Gebundenes Buch

Produktbeschreibung

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Seitenzahl: 284
• Erscheinungstermin: 1. Juli 2016
• Englisch
• Abmessung: 250mm x 175mm x 20mm
• Gewicht: 674g
• ISBN-13: 9780521862547
• ISBN-10: 052186254X
• Artikelnr.: 22558341

Autorenporträt

Jeffrey Cummings is Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA and Director of the UCLA Alzheimer's Disease Center.

Inhaltsangabe

1. Progress in Neurotherapeutics and Neuropsychopharmacology 2007 Jeffrey
L. Cummings; 2. A randomized trial comparing unilateral pallidotomy with
bilateral subthalamic nucleus stimulation in PD: perspectives for future
implication in clinical practice Rianne A. J. Esselink, Rob M. A. de Bie,
Rob J. de Haan, P. Richard Schuurman, Pepijn van den Munckhof and Johannes
D. Speelman; 3. The phase II futility clinical trial design Bernard Ravina
and Yuko Palesch; 4. Clinical trials in dementia Encarnita Raya-Ampil and
Jeffrey L. Cummings; 5. Comparative neuropsychological effects of
Lamotrigine and Topiramate in healthy volunteers Kimford J. Meador; 6.
Pilot clinical trial of NT-3 in CMT1A patients Zerife Sahenk; 7. New
directions in pediatric neuro-oncology practice: impact of the Children's
Cancer Group Study 9933, a phase II study of high-dose chemotherapy before
radiation in children with newly diagnosed high-grade astrocytoma Tobey J.
MacDonald; 8. Chemoradiotherapy for primary CNS lymphoma Antonio M. P.
Omuro, Joachim Yahalom and Lauren E. Abrey; 9. A double-blind, randomized
clinical trial to assess the augmentation with Nimodipine of antidepressant
therapy in the treatment of 'vascular depression' F. E. Taragano, P. M.
Bagnati and R. F. Allegri; 10. Repetitive transcranial magnetic
stimulation: a novel, noninvasive add-on treatment for medication-resistant
depression Tung-Ping Su and Chih-Chia Huang; 11. The NIMH MATRICS
initiative: development of a consensus cognitive battery Robert S. Kern,
Michael F. Green and Stephen R. Marder; 12. Review of a randomized
controlled trial of adjunctive Bupropion in the treatment of SSRI-induced
sexual dysfunction Anna Lembke and Charles DeBattista; 13. Trial-based
advances in the treatment of bipolar depression David E. Kemp, Keming Gao,
David J. Muzine, Prashant Gajwani and Joseph R. Calabrese; 14. Symptomatic
remission in patients with bipolar mania: results from a double-blind,
placebo-controlled trial of Risperidone monotherapy Srihari Gopal, John L.
Beyer, David C. Steffens and Michelle L. Kramer; 15. Olanzapine as
maintenance therapy in patients with bipolar I disorder Mauricio Tohen and
Daniel Yen Lin; 16. Can quality of life be improved in schizophrenia?
Results from a pragmatic, randomized controlled trial comparing Olanzapine
with first generation antipsychotics Mauricio Silva de Lima, Alan Breier
and Jair de Jesus Mari; 17. Combined behavioral and pharmacological
treatment of opioid-dependent adolescents: a randomized, controlled trial
Lisa A. Marsch.